SALL4, a Stem Cell Factor, Affects the Side Population by Regulation of the ATP-Binding Cassette Drug Transport Genes
Open Access
- 19 April 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (4), e18372
- https://doi.org/10.1371/journal.pone.0018372
Abstract
Our previous work shows that the stem cell factor SALL4 plays a central role in embryonic and leukemic stem cells. In this study, we report that SALL4 expression was higher in drug resistant primary acute myeloid leukemic patients than those from drug-responsive cases. In addition, while overexpression of SALL4 led to drug resistance in cell lines, cells with decreased SALL4 expression were more sensitive to drug treatments than the parental cells. This led to our investigation of the implication of SALL4 in drug resistance and its role in side population (SP) cancer stem cells. SALL4 expression was higher in SP cells compared to non-SP cells by 2–4 fold in various malignant hematopoietic cell lines. Knocking down of SALL4 in isolated SP cells resulted in a reduction of SP cells, indicating that SALL4 is required for their self-renewal. The SP phenotype is known to be mediated by members of the ATP-binding cassette (ABC) drug transport protein family, such as ABCG2 and ABCA3. Using chromatin-immunoprecipitation (ChIP), quantitative reverse transcription polymerase chain reaction (qRT-PCR) and electrophoretic mobility shift assay(EMSA), we demonstrated that SALL4 was able to bind to the promoter region of ABCA3 and activate its expression while regulating the expression of ABCG2 indirectly. Furthermore, SALL4 expression was positively correlated to those of ABCG2 and ABCA3 in primary leukemic patient samples. Taken together, our results suggest a novel role for SALL4 in drug sensitivity, at least in part through the maintenance of SP cells, and therefore may be responsible for drug-resistance in leukemia. We are the first to demonstrate a direct link between stem cell factor SALL4, SP and drug resistance in leukemia.Keywords
This publication has 39 references indexed in Scilit:
- PTEN/PI3K/Akt Pathway Regulates the Side Population Phenotype and ABCG2 Activity in Glioma Tumor Stem-like CellsCell Stem Cell, 2009
- Genome-wide analysis reveals Sall4 to be a major regulator of pluripotency in murine-embryonic stem cellsProceedings of the National Academy of Sciences of the United States of America, 2008
- SALL4 is a key regulator of survival and apoptosis in human leukemic cellsBlood, 2008
- Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenanceProceedings of the National Academy of Sciences of the United States of America, 2007
- CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemiaProceedings of the National Academy of Sciences of the United States of America, 2007
- Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cellsProceedings of the National Academy of Sciences of the United States of America, 2007
- SALL4, a novel oncogene, is constitutively expressed in human acute myeloid leukemia (AML) and induces AML in transgenic miceBlood, 2006
- Enhanced purification of fetal liver hematopoietic stem cells using SLAM family receptorsBlood, 2006
- Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cellNature Medicine, 1997
- Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo.The Journal of Experimental Medicine, 1996